Dashboard Market News Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Samsung Biologics Co Ltd banner

Samsung Biologics Co Ltd
KRX:207940

Watchlist Manager
Samsung Biologics Co Ltd Logo
Samsung Biologics Co Ltd
KRX:207940
Watchlist
Price: 1 415 000 KRW -0.56%
Market Cap: ₩65.5T
Write Note Create Alert Ask AI

Wall St Price Targets

Price Targets Summary
Samsung Biologics Co Ltd

Wall Street analysts forecast Samsung Biologics Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Samsung Biologics Co Ltd is 2 040 000 KRW with a low forecast of 1 616 000 KRW and a high forecast of 2 421 619.24 KRW.

Lowest Forecast
Wall Street Target
₩1 616 000
14% Upside
Average Forecast
Wall Street Target
₩2 040 000
44% Upside
Highest Forecast
Wall Street Target
₩2 421 619.24
71% Upside
Lowest Forecast
Price Target
1 616 000 KRW
14% Upside
Average Forecast
Price Target
2 040 000 KRW
44% Upside
Highest Forecast
Price Target
2 421 619.24 KRW
71% Upside
Samsung Biologics Co Ltd Competitors:
Price Targets

Revenue
Forecast

41% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat
41% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat

Over the last 11 years, the compound annual growth rate for Revenue has been 41%. The projected CAGR for the next 7 years is 14%.

What are analyst estimates?

Gross Profit
Forecast

N/A
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat
N/A
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat

The compound annual growth rate for Gross Profit over the next 3 years is 16%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat
N/A
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat

The compound annual growth rate for Operating Income over the next 7 years is 14%.

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat
N/A
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat

The compound annual growth rate for Pre-Tax Income over the next 3 years is 16%.

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
8%
Average Beat
N/A
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
8%
Average Beat

The compound annual growth rate for Net Income over the next 3 years is 12%.

What are analyst estimates?

Continue Research

Summary
intrinsic value, competitors valuation, and company profile.
DCF Valuation
stock valuation using Discount Cash Flow valuation method.
Relative Valuation
stock valuation using valuation multiples.
Wall St Estimates
price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is Samsung Biologics Co Ltd's stock price target?
Price Target
2 040 000 KRW

According to Wall Street analysts, the average 1-year price target for Samsung Biologics Co Ltd is 2 040 000 KRW with a low forecast of 1 616 000 KRW and a high forecast of 2 421 619.24 KRW.

What is the Revenue forecast for Samsung Biologics Co Ltd?
Projected CAGR
14%

Over the last 11 years, the compound annual growth rate for Revenue has been 41%. The projected CAGR for the next 7 years is 14%.

What is the Gross Profit forecast for Samsung Biologics Co Ltd?
Projected CAGR
16%

The compound annual growth rate for Gross Profit over the next 3 years is 16%.

What is the Operating Income forecast for Samsung Biologics Co Ltd?
Projected CAGR
14%

The compound annual growth rate for Operating Income over the next 7 years is 14%.

What is the Pre-Tax Income forecast for Samsung Biologics Co Ltd?
Projected CAGR
16%

The compound annual growth rate for Pre-Tax Income over the next 3 years is 16%.

What is the Net Income forecast for Samsung Biologics Co Ltd?
Projected CAGR
12%

The compound annual growth rate for Net Income over the next 3 years is 12%.

Back to Top
ALPHA SPREAD
Follow us
Join 357,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.